Cyrex Launches BiomeBurden™ for Immune Sensitivity Testing of Microbial, Yeast and Mold Triggers

PHOENIX, July 7, 2025 /PRNewswire/ -- Cyrex Laboratories, a clinical laboratory specializing in functional immunology and autoimmunity, today announced the launch of BiomeBurden™, its newest innovation in gut biome testing. This advanced 3-panel testing approach is designed to uncover multiple immune responses to microbes, yeast, and mold, including antibodies, lymphocytes, and T cells.

The foundational MycoBiomeBurden panel screens for 6 key Candida species, multiple Candida Albican virulence factors such as germ tube and candidalysin, and several food-derived molds. The second panel MicroBiomeBurden expands detection to several cross-reactive tissue antigens, 3 species of aerobic bacteria, and 4 species of anaerobic bacteria. The third panel, BiomeBurden Complete, includes the first two panels plus several flow cytometry tests for T-cell function and lymphocyte activity of Th1, Th2, and Th17 —all critical indicators of potential immune response to the tested antigens.

In recent years, both patients and healthcare providers have become increasingly aware of the important role that the gut microbiome plays in supporting immune health and balance. When this delicate balance is disrupted—especially by an overgrowth of certain fungal species—it can trigger chronic inflammation and impact overall well-being. Candida species, while naturally present in the body, can become problematic in certain individuals when they grow out of balance. This overgrowth has been linked to ulcerative colitis, liver autoimmunity, Rett syndrome, and other autoimmune conditions. By identifying these imbalances early, there is an opportunity to better understand the root causes of chronic symptoms and take proactive steps toward improved long-term health.

"This launch marks a key milestone for our company as we continue to transform how people understand and manage their health," said Mark McDonough, CEO of Cyrex Laboratories. "With BiomeBurden™, Cyrex is redefining microbial testing by focusing on immune activation—not just presence of antigens—to reveal how the body is actively responding. We have designed these panels to empower healthcare practitioners to uncover hidden microbial triggers through an expanded screening of potential immune responses that may drive chronic conditions. It's a more personalized, preventive approach—one focused on identifying root causes, not just managing symptoms."

BiomeBurden is the result of over 20 years of research and development by Aristo Vojdani PhD, considered the father of Functional Medicine and a pioneer in this field with over 20 patents and numerous industry-changing innovations.

"Unlike traditional stool or swab tests that focus primarily on the gut, the BiomeBurden™ blood test offers a more comprehensive view of the body's immune response to fungal and microbial triggers," said Dr. Vojdani, Chief Scientific Advisor of Cyrex. "By analyzing immune markers in the blood, we can assess not only the presence of specific organisms but also how the immune system is reacting across multiple systems—not just the gut. This provides clinicians with a better understanding of how the mycobiome and microbiome contribute to autoimmunity, as well as a deeper, more holistic understanding of a patient's overall immune health." 

All Cyrex Arrays are available to consumers exclusively through an order from a physician or other licensed healthcare professional. To learn more about the BiomeBurden test series or any of the many other Cyrex Arrays that are part of the Cyrex System, please visit www.joincyrex.com for additional information.

About Cyrex Laboratories:
Cyrex Laboratories is a clinical immunology laboratory specializing in a proactive, personalized patient- focused approach to functional immunology and autoimmunity. Our laboratory offers multi-tissue antibody testing for early detection and monitoring of today's complex autoimmune conditions. It develops innovative testing arrays through continuous collaboration with leading experts in medical research and clinical practice. The Cyrex system is built on several pillars of excellence to include the antigen purification system, the optimized antigen concentration, and the antigen-specific validation process. Cyrex is based in Phoenix, Arizona, USA and is CLIA licensed in the United States.

Media Contact:
Olipriya Das, PhD
646-942-5588 | [email protected]

Robert Haney, PhD
401-632-9316 | [email protected] 

SOURCE Cyrex Laboratories